• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Phage Displayed HBV Core Antigen with Immunogenic Activity
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Applied Biochemistry and Biotechnology
Yazar(lar) :
Aylin Ozdemir Bahadir , Bertan Koray Balcioglu , Kamil Serkan Uzyol , Ibrahim Hatipoglu , Ibrahim Sogut , Aynur Basalp , Berrin Erdag
Konu :
Molecular Biology, Applied Microbiology and Biotechnology, Biochemistry, General Medicine, Bioengineering, Biotechnology
Yıl :
2011
Bertan Koray Balcioglu
Tam Metin
Kaydet Alıntıla
Hepatitis B is a major public health problem worldwide, which may lead to chronic liver diseases such as cirrhosis and hepatocellular carcinoma. The hepatitis B core antigen (HBcAg) is one of the major viral proteins, which forms the inner core of hepatitis B virus (HBV) particles. In this study, filamentous bacteriophage M13 was genetically modified to display the polypeptides of HBcAg in order to develop an alternative carrier system. HBcAg gene was inserted into the minor coat protein (pIII) gene of M13, and HBcAg was expressed on the phage surface as a whole protein. Antigenicity and immunogenicity of HBcAg were tested by immunizing BALB/c mice three times with HBcAg-displaying recombinant phages. After successful immunization, one of the mice with high antibody titer to HBcAg was selected for fusion, and four monoclonal antibodies specific for HBcAg were developed. This result showed that HBcAg-displaying recombinant bacteriophages are immunogenic and can potentially be used for the development of monoclonal antibodies.
DOI : 10.1007/s12010-011-9365-1
Anahtar Kelimeler : HBcAg, Phage display, M13 phage, Immune response, ELISA, Monoclonal antibody
ISSN: 0273-2289 1559-0291
Sayı: 7-8
Cilt: 165
Sayfa: 1437-1447
2
SARS-CoV-2 neutralizing antibody development strategies
Araştırma Makalesi

Araştırma Makalesi
Open Access
Kaynak :
Aperta - TÜBİTAK Açık Arşivi
Dergi:
TURKISH JOURNAL OF BIOLOGY
Yazar(lar) :
Aylin Ozdemir Bahadir , Saban Tekin , Hivda Ulbegi Polat , Muge Serhatli , Filiz Kaya , Fatima Yucel , Hasan Umit Ozturk , Melis Denizci Oncu , Bertan Koray Balcioglu
Yıl :
2020
Bertan Koray Balcioglu
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
DOI : 10.3906/biy-2005-91
Sayi :44
issue :3
Sayfa :203-214
Sınıflandırma :
Biyotıp %100
Viroloji %100

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler